Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
7
Neutral
3
Bullish
4
Bearish
23
Neutral
3
Bullish
20
Bearish
16
Neutral
0
Bullish
16
Bearish
16
Neutral
0
Bullish
16
Bearish
16
Neutral
0
Bullish
16
Bearish
16
Neutral
0
Bullish
16
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stock
HealthCare Global Enterprises (HCG) operates India’s largest private oncology network under the HCG brand, providing comprehensive cancer care, advanced radiation and surgical oncology, and specialized diagnostics through the Triesta molecular lab; the company also operates an international presence and has recently completed the divestment of its fertility business to sharpen focus on oncology.
HCG reported Q1 FY27 revenue of INR6,951 million, up circa 13% year-on-year, driven by an 11% increase in patient volumes and a 2% ARPP improvement; non-institutional revenue grew 17% year-on-year and the payor mix shifted favorably from 67% to 69% non-institutional contribution, improving the quality of earnings.
Operational momentum translated into adjusted EBITDA of INR1,339 million, a 20% year-on-year increase, with EBITDA margin expanding to 19.4% from 18.2%, reflecting margin-accretive steps such as discontinuation of certain low-margin chemo drugs and improved payor mix alongside cost and productivity initiatives.
HCG is executing a material capacity program with 121 beds added in Q1, a newly commissioned 132-bed North Bangalore hospital contributing INR67 million, and a disclosed roadmap of 65 beds in FY27 and 520 beds across FY28–FY29, with nearly 60% of additions via brownfield projects to enable faster, lower-capex growth.
Balance sheet and execution moves include a completed rights issue used for INR170 crore debt repayment and strategic deployment to increase stake in Vizag; management expects interest cost moderation, operating cash generation improving, and disciplined capex with maintenance capex guidance near INR100 crore annually.
Healthcare Services
Hospital
9,039 Cr
Low Risk
271.8
60.3
0.9
6.8
770.80
513.40
Sales CAGR
Profit CAGR
ROE
ROCE
Healthcare Global Enterprises Ltd (HCG) is currently trading at 619.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
HealthCare Global Enterprises (HCG) operates India’s largest private oncology network under the HCG brand, providing comprehensive cancer care, advanced radiation and surgical oncology, and specialized diagnostics through the Triesta molecular lab; the company also operates an international presence and has recently completed the divestment of its fertility business to sharpen focus on oncology. HCG reported Q1 FY27 revenue of INR6,951 million, up circa 13% year-on-year, driven by an 11% increase in patient volumes and a 2% ARPP improvement; non-institutional revenue grew 17% year-on-year and the payor mix shifted favorably from 67% to 69% non-institutional contribution, improving the quality of earnings. Operational momentum translated into adjusted EBITDA of INR1,339 million, a 20% year-on-year increase, with EBITDA margin expanding to 19.4% from 18.2%, reflecting margin-accretive steps such as discontinuation of certain low-margin chemo drugs and improved payor mix alongside cost and productivity initiatives. HCG is executing a material capacity program with 121 beds added in Q1, a newly commissioned 132-bed North Bangalore hospital contributing INR67 million, and a disclosed roadmap of 65 beds in FY27 and 520 beds across FY28–FY29, with nearly 60% of additions via brownfield projects to enable faster, lower-capex growth. Balance sheet and execution moves include a completed rights issue used for INR170 crore debt repayment and strategic deployment to increase stake in Vizag; management expects interest cost moderation, operating cash generation improving, and disciplined capex with maintenance capex guidance near INR100 crore annually.
Over the past 52 weeks, Healthcare Global Enterprises Ltd has traded between a low of ₹513.40 and a high of ₹770.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Healthcare Global Enterprises Ltd has a market capitalization of approximately 9,038.76. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Healthcare Global Enterprises Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 271.76 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 9,038.76 Cr, Healthcare Global Enterprises Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Healthcare Global Enterprises Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Healthcare Global Enterprises Ltd is 271.76. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
HCG has outlined a plan to add about 1,000 beds over the next five years, with a mix of brownfield and greenfield expansion.
The text reports a consolidated net profit of ₹2.17 crore for Q4 FY26, down 70.5% year-on-year from ₹7.36 crore in Q4 FY25.
Healthcare Global Enterprises Ltd reported a standalone net loss of Rs -7.90 crore in Q3 FY25-26 (often rounded to about Rs -7 crore in summaries).
HCG is scheduled to announce its audited Q4 and FY26 results on May 20, 2026.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1247.40 | 12,669 Cr | 42.44 | 7.39 | 0.28 | 17.05 | 17.00 | 10.09 | ||
223.85 | 9,669 Cr | 32.58 | 4.81 | 0.00 | 12.77 | 17.33 | 10.55 | ||
983.20 | 9,474 Cr | 52.15 | 5.05 | 0.00 | 9.85 | 11.09 | 7.65 | ||
605.40 | 9,039 Cr | 271.76 | 6.79 | 0.00 | 2.90 | 7.81 | 0.85 | ||
263.35 | 8,633 Cr | 46.26 | 5.30 | 0.08 | 11.43 | 12.76 | 7.29 | ||
732.50 | 7,926 Cr | 180.86 | 8.86 | 0.00 | 11.10 | 10.73 | 0.00 | ||
5881.05 | 6,434 Cr | 25.46 | 4.88 | 0.26 | 18.53 | 20.76 | 12.41 | ||
| Median: 7 Co. | — | 732.50 | 9,039 Cr | 46.26 | 5.30 | 0.00 | 11.43 | 12.76 | 7.65 |
